Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

Overview

• Gender

  ALL

• Age

  18 Years or older

• Phase

  PHASE3

• Study Type

  INTERVENTIONAL

• Location

  Novartis Investigative Site (Coimbra)
  Novartis Investigative Site (Lisboa)
  Novartis Investigative Site (Lisbon)
  Novartis Investigative Site (Porto)
  Novartis Investigative Site (Porto)
  

• Clinicaltrial.gov

  https://classic.clinicaltrials.gov/ct2/show/NCT02074982

Summary

This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis

Conditions

Chronic Plaque Type Psoriasis

Eligibility

Inclusion Criteria:

* patients with moderate to severe plaque type psoriasis for at least 6 months before randomization
* patients eligible for systemic therapy with inadequately controlled psoriasis

Exclusion Criteria:

* forms of sporiasis other than plaque type psoriasis
* previous exposure to secukinumab, ustekinumab, or other biologic drugs targeting (IL)-17A or IL-17RA

Other protocol-defined inclusion/exclusion criteria may apply

Details